跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AIMOVIG - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
AIMOVIG
Authorized
STANDARD
AIMOVIG
novartis pharmaceuticals canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
47766d7be65391fe
Company
novartis pharmaceuticals canada inc
Type
Standard
Approval Details
Approval Id
47766d7be65391fe
Drug Approval Canada Name
AIMOVIG
Product Name
AIMOVIG
Status
Marketed
Status Date
2019-05-22
Original Market Date
2019-05-22
Din
02487306
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Schedule D , Prescription
Ahfs
28:32.12
Atc Original
N02CD01 ERENUMAB
Atc Name
n 02 cd 01
Aig Number
0160530002
Company Name
novartis pharmaceuticals canada inc
Company Address
100, 700 Rue Saint-Hubert, Montreal, Quebec, Canada, H2Y 0C1
Active Ingredients
ERENUMAB
140 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
47766d7be65391fe
Type
Standard
Back to Health Canada Approvals